Literature DB >> 26769006

Effect of anti-sclerostin therapy and osteogenesis imperfecta on tissue-level properties in growing and adult mice while controlling for tissue age.

Benjamin P Sinder1, William R Lloyd2, Joseph D Salemi1, Joan C Marini3, Michelle S Caird4, Michael D Morris2, Kenneth M Kozloff5.   

Abstract

Bone composition and biomechanics at the tissue-level are important contributors to whole bone strength. Sclerostin antibody (Scl-Ab) is a candidate anabolic therapy for the treatment of osteoporosis that increases bone formation, bone mass, and bone strength in animal studies, but its effect on bone quality at the tissue-level has received little attention. Pre-clinical studies of Scl-Ab have recently expanded to include diseases with altered collagen and material properties such as osteogenesis imperfecta (OI). The purpose of this study was to investigate the role of Scl-Ab on bone quality by determining bone material composition and tissue-level mechanical properties in normal wild type (WT) tissue, as well as mice with a typical OI GlyCys mutation (Brtl/+) in type I collagen. Rapidly growing (3-week-old) and adult (6-month-old) WT and Brtl/+ mice were treated for 5weeks with Scl-Ab. Fluorescent guided tissue-level bone composition analysis (Raman spectroscopy) and biomechanical testing (nanoindentation) were performed at multiple tissue ages. Scl-Ab increased mineral to matrix in adult WT and Brtl/+ at tissue ages of 2-4wks. However, no treatment related changes were observed in mineral to matrix levels at mid-cortex, and elastic modulus was not altered by Scl-Ab at any tissue age. Increased mineral-to-matrix was phenotypically observed in adult Brtl/+ OI mice (at tissue ages>3wks) and rapidly growing Brtl/+ (at tissue ages>4wks) mice compared to WT. At identical tissue ages defined by fluorescent labels, adult mice had generally lower mineral to matrix ratios and a greater elastic modulus than rapidly growing mice, demonstrating that bone matrix quality can be influenced by animal age and tissue age alike. In summary, these data suggest that Scl-Ab alters the matrix chemistry of newly formed bone while not affecting the elastic modulus, induces similar changes between Brtl/+ and WT mice, and provides new insight into the interaction between tissue age and animal age on bone quality.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anabolic therapy; Bone quality; Nanoindentation; Osteogenesis imperfecta; Raman spectroscopy; Sclerostin antibody

Mesh:

Substances:

Year:  2016        PMID: 26769006      PMCID: PMC4757447          DOI: 10.1016/j.bone.2016.01.001

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  35 in total

1.  Microstructure and nanomechanical properties in osteons relate to tissue and animal age.

Authors:  Jayme Burket; Samuel Gourion-Arsiquaud; Lorena M Havill; Shefford P Baker; Adele L Boskey; Marjolein C H van der Meulen
Journal:  J Biomech       Date:  2010-11-12       Impact factor: 2.712

2.  Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats.

Authors:  Xiaodong Li; Kelly S Warmington; Qing-Tian Niu; Franklin J Asuncion; Mauricio Barrero; Mario Grisanti; Denise Dwyer; Brian Stouch; Theingi M Thway; Marina Stolina; Michael S Ominsky; Paul J Kostenuik; William S Simonet; Chris Paszty; Hua Zhu Ke
Journal:  J Bone Miner Res       Date:  2010-07-16       Impact factor: 6.741

3.  Repeated freeze-thawing of bone tissue affects Raman bone quality measurements.

Authors:  John-David P McElderry; Matthew R Kole; Michael D Morris
Journal:  J Biomed Opt       Date:  2011-07       Impact factor: 3.170

Review 4.  New perspectives on osteogenesis imperfecta.

Authors:  Antonella Forlino; Wayne A Cabral; Aileen M Barnes; Joan C Marini
Journal:  Nat Rev Endocrinol       Date:  2011-06-14       Impact factor: 43.330

5.  Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody.

Authors:  Desmond Padhi; Graham Jang; Brian Stouch; Liang Fang; Edward Posvar
Journal:  J Bone Miner Res       Date:  2011-01       Impact factor: 6.741

6.  Quantitative polarized Raman spectroscopy in highly turbid bone tissue.

Authors:  Mekhala Raghavan; Nadder D Sahar; Robert H Wilson; Mary-Ann Mycek; Nancy Pleshko; David H Kohn; Michael D Morris
Journal:  J Biomed Opt       Date:  2010 May-Jun       Impact factor: 3.170

Review 7.  The contribution of the extracellular matrix to the fracture resistance of bone.

Authors:  Jeffry S Nyman; Alexander J Makowski
Journal:  Curr Osteoporos Rep       Date:  2012-06       Impact factor: 5.096

8.  Alendronate treatment of the brtl osteogenesis imperfecta mouse improves femoral geometry and load response before fracture but decreases predicted material properties and has detrimental effects on osteoblasts and bone formation.

Authors:  Thomas E Uveges; Kenneth M Kozloff; Jennifer M Ty; Felicia Ledgard; Cathleen L Raggio; Gloria Gronowicz; Steven A Goldstein; Joan C Marini
Journal:  J Bone Miner Res       Date:  2009-05       Impact factor: 6.741

9.  Effects of tissue age on bone tissue material composition and nanomechanical properties in the rat cortex.

Authors:  Eve Donnelly; Adele L Boskey; Shefford P Baker; Marjolein C H van der Meulen
Journal:  J Biomed Mater Res A       Date:  2010-03-01       Impact factor: 4.396

10.  Ultra-structural defects cause low bone matrix stiffness despite high mineralization in osteogenesis imperfecta mice.

Authors:  Maximilien Vanleene; Alexandra Porter; Pascale-Valerie Guillot; Alan Boyde; Michelle Oyen; Sandra Shefelbine
Journal:  Bone       Date:  2012-03-16       Impact factor: 4.398

View more
  14 in total

1.  Finite element analysis of bone strength in osteogenesis imperfecta.

Authors:  Peter Varga; Bettina M Willie; Chris Stephan; Kenneth M Kozloff; Philippe K Zysset
Journal:  Bone       Date:  2020-01-22       Impact factor: 4.398

Review 2.  Vibrational spectroscopic techniques to assess bone quality.

Authors:  E P Paschalis; S Gamsjaeger; K Klaushofer
Journal:  Osteoporos Int       Date:  2017-04-05       Impact factor: 4.507

3.  Bone mineral properties in growing Col1a2(+/G610C) mice, an animal model of osteogenesis imperfecta.

Authors:  Marco Masci; Min Wang; Laurianne Imbert; Aileen M Barnes; Lyudmila Spevak; Lyudmila Lukashova; Yihe Huang; Yan Ma; Joan C Marini; Christina M Jacobsen; Matthew L Warman; Adele L Boskey
Journal:  Bone       Date:  2016-04-13       Impact factor: 4.398

4.  Single dose of bisphosphonate preserves gains in bone mass following cessation of sclerostin antibody in Brtl/+ osteogenesis imperfecta model.

Authors:  Joseph E Perosky; Basma M Khoury; Terese N Jenks; Ferrous S Ward; Kai Cortright; Bethany Meyer; David K Barton; Benjamin P Sinder; Joan C Marini; Michelle S Caird; Kenneth M Kozloff
Journal:  Bone       Date:  2016-09-15       Impact factor: 4.398

Review 5.  Application of anti-Sclerostin therapy in non-osteoporosis disease models.

Authors:  Christina M Jacobsen
Journal:  Bone       Date:  2016-10-22       Impact factor: 4.398

6.  Canalization Leads to Similar Whole Bone Mechanical Function at Maturity in Two Inbred Strains of Mice.

Authors:  Stephen H Schlecht; Lauren M Smith; Melissa A Ramcharan; Erin Mr Bigelow; Bonnie T Nolan; Noah J Mathis; Amber Cathey; Eugene Manley; Rajasree Menon; Richard C McEachin; Joseph H Nadeau; Karl J Jepsen
Journal:  J Bone Miner Res       Date:  2017-02-27       Impact factor: 6.741

7.  Low Dose of Bisphosphonate Enhances Sclerostin Antibody-Induced Trabecular Bone Mass Gains in Brtl/+ Osteogenesis Imperfecta Mouse Model.

Authors:  Diana Olvera; Rachel Stolzenfeld; Joan C Marini; Michelle S Caird; Kenneth M Kozloff
Journal:  J Bone Miner Res       Date:  2018-05-07       Impact factor: 6.741

8.  PTH(1-34) and zoledronic acid have differing longitudinal effects on juvenile mouse femur strength and morphology.

Authors:  Christopher M Bartlow; Megan E Oest; Kenneth A Mann; Nicholas D Zimmerman; Bilal B Butt; Timothy A Damron
Journal:  J Orthop Res       Date:  2016-10-03       Impact factor: 3.494

Review 9.  Tissue-Level Mechanical Properties of Bone Contributing to Fracture Risk.

Authors:  Jeffry S Nyman; Mathilde Granke; Robert C Singleton; George M Pharr
Journal:  Curr Osteoporos Rep       Date:  2016-08       Impact factor: 5.096

10.  A xenograft model to evaluate the bone forming effects of sclerostin antibody in human bone derived from pediatric osteogenesis imperfecta patients.

Authors:  Rachel K Surowiec; Lauren F Battle; Ferrous S Ward; Stephen H Schlecht; Basma M Khoury; Christopher Robbins; Edward M Wojtys; Michelle S Caird; Kenneth M Kozloff
Journal:  Bone       Date:  2019-10-31       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.